Restless Legs Syndrome—An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases

Clin Genitourin Cancer. 2015 Oct;13(5):e385-6. doi: 10.1016/j.clgc.2015.04.007. Epub 2015 May 1.

Authors

Marie-Claire Desax¹, Thomas Hundsberger², Christian Rothermundt³, Aurelius Omlin³, Silke Gillessen³

Affiliations

¹ Department of Medical Oncology/Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland. Electronic address: marie-claire.desax@kssg.ch.
² Department of Medical Oncology/Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland; Department of Neurology, Cantonal Hospital St Gallen, St Gallen, Switzerland.
³ Department of Medical Oncology/Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland.

PMID: 26048855
DOI: 10.1016/j.clgc.2015.04.007

No abstract available

Keywords: Adverse event; Castration-resistant prostate cancer; Enzalutamide; Prostate cancer; Restless Legs Syndrome.

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents / adverse effects*
Benzamides
Humans
Male
Nitriles
Phenylthiohydantoin / adverse effects
Phenylthiohydantoin / analogs & derivatives*
Prostatic Neoplasms, Castration-Resistant / drug therapy
Restless Legs Syndrome / chemically induced*

Substances

Antineoplastic Agents
Benzamides
Nitriles
Phenylthiohydantoin
enzalutamide